Business Context and Reporting Period
This Form 8-K Current Report was filed by Inotek Pharmaceuticals Corporation on January 11, 2016. The filing reports the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation: an option grant to purchase 24,000 shares of Common Stock at an exercise price of $8.89 per share.
Material Changes
The material change reported is the election of Carsten Boess as a Class II independent director on January 11, 2016. Mr. Boess was also appointed to the Audit Committee. His term will last until the annual meeting of stockholders following the year ending December 31, 2015, or until earlier death, resignation, or removal.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding the company's business strategy or future financial performance. It notes that Mr. Boess will receive compensation in the same manner as other non-employee directors and will enter into a standard indemnification agreement. No risks or contingencies are discussed in this specific report.
Important Facts for Investors to Verify
- Carsten Boess has been appointed as an independent director and member of the Audit Committee.
- Mr. Boess received an option grant for 24,000 shares at $8.89 per share, vesting 25% after one year and the remainder monthly thereafter.
- Mr. Boess brings prior experience as CFO of Synageva BioPharma (now Alexion) and Chief Business Officer at Kiniksa Pharmaceuticals.
- The filing does not contain updated financial results or operational metrics for the company.